Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review

Background In trials of monoclonal antibodies against calcitonin gene-related peptide or its receptor for prevention of episodic migraine, we observed two problematic aspects: a) The graphic presentations; b) the methods of calculating “response rates” (≥50% decrease of monthly migraine days from baseline). Observations Decrease in monthly migraine days is presented, over time, in figures on a downward (negative) scale from zero at baseline,...